A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Their cancer is locally advanced, unresectable, or metastatic. Locally advanced means the cancer has spread to tissue close by. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. In South Korea, VYLOY is approved for the treatment of gastric cancer or GEJ cancer. The people in this study will receive VYLOY as part of their usual treatment for their cancer. In standard clinical practice VYLOY is given to people slowly through a tube into a vein. The main aim of the study is to collect information in a real-world setting about the safety of VYLOY in people with gastric cancer or GEJ cancer in clinics in South Korea. This study will also help researchers learn how long people's gastric cancer or GEJ cancer stays stable. This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the sponsor (Astellas). The study will last about 1 year (54 weeks).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci, którzy otrzymują leczenie za pomocą wstrzyknięć VYLOY zgodnie z zatwierdzoną etykietą leku
✗ Disqualifies
- •Pacjenci, dla których VYLOY jest przeciwwskazany zgodnie z zatwierdzoną etykietą leku
- •Pacjenci, którzy biorą udział lub mają zaplanowany udział w innych badaniach klinicznych z eksperymentalnymi lekami
Simplified criteria — AI translation
Trial details
- Last updated (source)
- July 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (13)
KR82010
Goyang-si, South Korea
KR82008
Suwon, South Korea
KR82009
Suwon, South Korea
KR82006
Yangsan, South Korea
KR82012
Hwasun Gun, South Korea
KR82001
Seoul, South Korea
KR82002
Seoul, South Korea
KR82003
Seoul, South Korea
KR82004
Seoul, South Korea
KR82005
Seoul, South Korea
KR82007
Seoul, South Korea
KR82011
Seoul, South Korea
KR82013
Seoul, South Korea
Trial contact
Astellas Pharma Global Development, Inc.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.